Analyzing AIM ImmunoTech (NYSE:AIM) & Valneva (NASDAQ:VALN)

AIM ImmunoTech (NYSE:AIM) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.

Earnings and Valuation

This table compares AIM ImmunoTech and Valneva”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AIM ImmunoTech	$200,000.00	71.67	-$28.96 million	($0.47)	-0.48
Valneva	$165.52 million	1.96	-$109.78 million	($0.13)	-30.77

AIM ImmunoTech has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

AIM ImmunoTech has a beta of -0.36, indicating that its share price is 136% less volatile than the S&P 500. Comparatively, Valneva has a beta of 2.17, indicating that its share price is 117% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for AIM ImmunoTech and Valneva, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AIM ImmunoTech	0	0	2	0	3.00
Valneva	0	0	2	0	3.00

AIM ImmunoTech presently has a consensus target price of $3.00, indicating a potential upside of 1,233.33%. Valneva has a consensus target price of $18.50, indicating a potential upside of 362.50%. Given AIM ImmunoTech’s higher probable upside, equities analysts plainly believe AIM ImmunoTech is more favorable than Valneva.

Profitability

This table compares AIM ImmunoTech and Valneva’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AIM ImmunoTech	-12,594.21%	-421.73%	-147.54%
Valneva	-4.35%	-3.93%	-1.42%

Insider & Institutional Ownership

12.0% of AIM ImmunoTech shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 0.0% of AIM ImmunoTech shares are held by insiders. Comparatively, 14.9% of Valneva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Valneva beats AIM ImmunoTech on 7 of the 12 factors compared between the two stocks.

About AIM ImmunoTech

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.